Stockreport

atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF VLS-01 is designed to induce a short psychedelic experience, allowing for a total in-clinic treatment of 2-hours, consistent with an established commercial paradigm in i [Read more]